Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma
Dual targeting of PD-L1 and 4-1BB overcomes dendritic cell-mediated #Lenalidomide resistance in #FollicularLymphoma by restoring immune activation and tumor cell #Autophagy, highlighting a promising #Immunotherapy approach.
#STTT #OpenAccess: doi.org/10.1038/s413...
The FLIPI24 prognostic model performs excellently in cases of newly diagnosed #follicularLymphoma, demonstrating superiority over existing models. Published in @ascopost.bsky.social.
https://bit.ly/4uTbTuo
#lymsm
After 15 years of follow-up, a “substantial subset” of patients with previously untreated advanced #follicularLymphoma achieved cure with CHOP-based chemoimmunotherapy. Published in @jamaoncology.com and @cancertherapyadv.bsky.social.
https://bit.ly/46TSlM0
#lymsm
Pirtobrutinib was effective and well-tolerated among a cohort of patients with heavily pretreated R/R #follicularLymphoma. Published in @bloodjournals.hematology.org.
https://bit.ly/4lnz63e
#lymsm
Figure 1. Survival Curves with three graphs: A) overall vs progression-free survival, B) overall survival, and C) progression-free survival. Each shows survival percentages over 20 years post-randomization, comparing 'R-CHOP' and 'CHOP-RIT' treatments.
Fifteen-year follow-up of the SWOG S0016 trial demonstrates that 42% of patients with advanced-stage #FollicularLymphoma treated with CHOP-based chemoimmunotherapy achieve functional cure.
ja.ma/4s6Fm1F
Treatment with rituximab plus epcoritamab achieves rapid and deep responses in #follicularLymphoma patients with a high tumor burden, with a 1-year progression-free survival rate of more than 95%. From @cancertherapyadv.bsky.social.
https://bit.ly/49dK3Pd
#lymsm
The @fda.gov has granted accelerated approval to Lunsumio Velo™, a SC formulation of mosunetuzumab-axgb, for the treatment of adult patients with R/R #follicularLymphoma after 2 or more lines of systemic therapy. From @medicalprofref.bsky.social.
https://bit.ly/4qoYAP8
#lymsm
Compared with #obinutuzumab monotherapy, the next-gen BTK inhibitor #zanubrutinib in combination with #obinutuzumab led to improved survival in patients with #FollicularLymphoma, resulting in ORRs of 70.3% vs. 44.4% and PFS of 22.1 vs. 10.3 months: https://ow.ly/qzV250XMMvj
#HemeSky #MedSky
Tafasitamab Plus Lenalidomide and Rituximab Nets #EuropeanApproval in R/R #FollicularLymphoma
www.onclive.com/view/tafasit...
🔗 Read more: bit.ly/ONCOnews18D-02
#ONCOnews #OncoAlert #OncEd #OncologyNews #EUApproval #FollicularLymphoma #Hematology
Epcoritamab reduced the risk for death by 79%. Presented at #ASH25, by Dr Falchi of @mskcancercenter.bsky.social covered by @cancertherapyadv.bsky.social.
https://bit.ly/4q4fQcb
#lymsm #follicularLymphoma
Interim data from the phase 3 EPCORE FL-1 trial suggests that adding the CD3xCD20 bispecific antibody epcoritamab to lenalidomide plus rituximab markedly improves response rates and PFS in R/R #follicularLymphoma. Presented at #ASH25.
https://bit.ly/3KndbLP
#lymsm
Treatment with rituximab plus epcoritamab achieves rapid and deep responses in #follicularLymphoma patients with a high #tumor burden, with a 1-year progression-free survival rate of more than 95%. Presented by Reid Merryman, MD of @danafarber.bsky.social.
https://bit.ly/4aB6sbA
#lymsm
In patients with #follicularLymphoma being treated in the third-line setting or later, liso-cel therapy is associated with durable responses. Presented at #ASH25 by Sairah Ahmed, MD from @mdanderson.bsky.social
https://bit.ly/44aFe7Y
#lymsm
New in Blood Cancer Discovery: IRF4 Shapes the #Lymphoma TME buff.ly/7wbtXW8
Elevated IRF4 expression in #follicularlymphoma cells may contribute to immune evasion and aggressive disease features by impairing B-cell antigen presentation, altering cytokine signaling, and rewiring metabolism.
Roche’s Lunsumio SC Granted Conditional EU Approval for Relapsed/Refractory Follicular Lymphoma
🔗 Full article: stellanews.life/technology_c...
#Roche #Lunsumio #Mosunetuzumab #FollicularLymphoma #Hematology #CancerTherapy #Subcutaneous #OncologyNews #Biopharma
Patients in the #US and #EU with #follicularlymphoma (FL) have new treatment options, thanks to #regulatoryapprovals for #Roche's Lunsumio and #AbbVie/Genmab's Epkinly.
#Lymphopoiesiscont36 #NonHodgkinsLymphoma #BurkittLymphoma #FollicularLymphoma #MantleCellLymphoma #MarginalZoneLymphoma #DiffuseLargeBCellLymphoma #PrimaryCNSLymphoma #BCellLymphoma #LymphomaAwareness #Oncology #CancerEducation #MedicalNotes #Hematology #ChromosomalTranslocation #GeneticMutations #MedicalInfographic #Histopathology #MedicalLearning #MedStudent #Pathology
#Lymphopoiesiscont36
#NonHodgkinsLymphoma #BurkittLymphoma #FollicularLymphoma #MantleCellLymphoma #MarginalZoneLymphoma #DiffuseLargeBCellLymphoma #PrimaryCNSLymphoma #BCellLymphoma #LymphomaAwareness #Oncology #CancerEducation #MedicalNotes #Hematology #ChromosomalTranslocation #GeneticMutations
Recently, Gottfried von Keudell shared the long-term follow-up results from the Phase II ELM-2 study evaluating the efficacy of the bispecific antibody odronextamab in patients with R/R #FollicularLymphoma.
Watch here:
👉 buff.ly/6GUNfkY 👈
#ImmunoOnc #LYMsm #CTSM #TrialUpdate #SOHO2025 #MedSky
The first trial of #Rituximab plus #Lenalidomide in newly diagnosed #FollicularLymphoma in China identified PU.1 as a key regulator of PD-L1/4-1BBL signaling and highlighted dual PD-L1/4-1BB targeting as a promising treatment. #medsky
#OpenAccess in #STTT: doi.org/10.1038/s413...
AMP just published!
"Pure Red Cell Aplasia in Follicular Lymphoma with Bone Marrow Involvement and Isoniazid Exposure"
Full paper here:
www.actamedicaportuguesa.com/revista/inde...
#isoniazid #latenttuberculosis #drugtherapy #follicularlymphoma #pureredcellaplasia #rituximab #actamedicaportuguesa
Esp as the alternative salvage therapy of ruxolitinib on interstitial pneumonia after #longCOVID or #postCOVID syndrome with #follicularlymphoma in
2 #casereports with unvaccinated patients
cco.amegroups.org/article/view....
Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma #hematology #oncology #follicularlymphoma
www.onclive.com/view/acalabr...
Adding tafasitamab to lenalidomide plus rituximab combination is unlikely to reduce QoL outcomes, despite evidence that the addition may lead to clinically meaningful improvements in PFS in the R/R #follicularLymphoma setting. Presented at #SOHO2025.
https://bit.ly/4nkVg62
#lymsm
According to new long-term data, among patients with advanced-stage, asymptomatic low-tumor-burden #FollicularLymphoma, early #rituximab monotherapy delayed the TTNT to more than 15 years, compared with less than six years seen with watchful waiting: ow.ly/luEa50WRTVZ
#HemeSky #lymphoma #HemeOnc
Check out this new publication by lead author Paolo Strati in Nature Communications from a Phase 2 trial in patients with advanced #follicularlymphoma using Foresight CLARITY™, achieving ultra-sensitive #MRD detection and outcome prediction. Read here: bit.ly/3I3Vdg4
FYI: LucidQuest Views >>> Hematology Weekly News – August 11th 2025 #News #AML #CLL #follicularlymphoma #hematology Comment below!
ICYMI: LucidQuest Views >>> Hematology Weekly News – August 11th 2025 #News #AML #CLL #follicularlymphoma #hematology Comment below!
LucidQuest Views >>> Hematology Weekly News – August 11th 2025 #News #AML #CLL #follicularlymphoma #hematology Comment below!
📣 New ESMO #ClinicalPracticeGuideline on #lymphomas: evidence-based recommendations for all major #lymphoma subtypes, updated as needed as an ESMO Living Guideline, reflecting developments in Tx.
#DLBCL #PCNSL #FollicularLymphoma #HodgkinLymphoma #ESMOGuidelines
🔗 buff.ly/2ZYJc2c
